The blood-brain barrier and cancer: Transporters, treatment, and trojan horses

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1663-1674

  Deeken, John F ^a   Löscher, Wolfgang ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYCLOSPORIN; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ELACRIDAR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; IDARUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PROBENECID; SULFINPYRAZONE; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR; ANTINEOPLASTIC AGENT; CARRIER PROTEIN;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL MEMBRANE TRANSPORT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL RESEARCH; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; LUNG SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SYSTEMIC CIRCULATION; SYSTEMIC THERAPY; ANIMAL; BIOLOGICAL MODEL; BRAIN TUMOR; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; METASTASIS; METHODOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RADIOTHERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; RADIOTHERAPY;

EID: 34250177984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2854     Document Type: Review

References (86)

1. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-705.
2. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern ofmalignantmelanoma. A study of 216 autopsy cases. Am J Surg 1978;135:807-10.
3. Posner JB. Neurologic complications of cancer. Philadelphia: FA Davis Company; 1995.
4. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol 2004;52:199-215.
5. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. New York: WB Saunders; 1996.
6. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38:323-37.
7. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
8. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. JPhysiol 1990;429:47-62.
9. Hirase T, Staddon JM, Saitou M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997;110:1603-13.
10. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.
11. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90-105, 51.
12. Sugiyama Y, Kusuhara H, Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J Control Release 1999;62:179-86.
13. Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol 1999;5:556-69.
14. Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and P-glycoprotein - mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303:1029-37.
15. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
16. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005;76:22-76.
17. Golden PL, Pollack GM. Blood-brain barrier efflux transport. JPharm Sci 2003;92:1739-53.
18. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
19. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
20. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantification of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995;95:2205-14.
21. Lee JS, Paull K, Alvarez M, et al. Rhoadamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38.
22. Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 2002;38:339-48.
23. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
24. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003;55:83-105.
25. Cisternino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein - deficient mice. Pharm Res 2001;18:183-90.
26. Sawchuk RJ, Elmquist WF. Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev 2000;45:295-307.
27. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
28. Wang Q, Yang H, Miller DW, Elmquist WF. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 1995;211:719-26.
29. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem 1996;67:1688-93.
30. Kemper EM, van Zandbergen AE, Cleypool C, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003;9:2849-55.
31. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004;10:1493-503.
32. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
33. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004;53:173-8.
34. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005;77:503-14.
35. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999;96:3900-5.
36. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10:1295-312.
37. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 2004;311:449-55.
38. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
39. Wijnholds J, deLange EC, Scheffer GL, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000;105:279-85.
40. Sun H, Miller DW, Elmquist WF. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm Res 2001;18:1542-9.
41. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665-70.
42. Fetsch PA, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006;238:84-92.
43. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13:2059-63.
44. Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003;971:221-31.
45. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1(Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistant protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-82.
46. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004;64:3296-301.
47. Fricker G, Miller DS. Modulation of drug transporters at the blood-brain barrier. Pharmacology 2004;70:169-76.
48. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000;294:73-9.
49. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000;26:449-62.
50. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol (Berl) 2000;100:323-31.
51. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol Berl 1989;78:561-71.
52. Regina A, Demeule M, Laplante A, et al. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 2001;20:13-25.
53. Becker I, Becker KF, Meyermann R, Hollt V. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol (Berl) 1991;82:516-9.
54. Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM. MDR1P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 1996;149:853-8.
55. Haga S, Hinoshita E, Ikezaki K, et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 2001;92:211-9.
56. Rubin P, Gash DM, Hansen JT, Nelson DF, Williams JP. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol 1994;31:51-60.
57. Reinhold HS, Calvo W, Hopewell JW, van der Berg AP. Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys 1990;18:37-42.
58. Mima T, Toyonaga S, Mori K, Taniguchi T, Ogawa Y. Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol Res 1999;21:209-15.
59. McDonald N, Vykhodtseva N, Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys Med Biol 2006;51:793-807.
60. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer1986;58:832-9.
61. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989;7:916-22.
62. Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy - a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18:3400-8.
63. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non - small cell lung cancer. Oncology 2000;59:291-5.
64. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non - small cell lung cancer: a phase II study. Cancer Invest 2002;20:293-302.
65. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small cell lung cancer also after whole-brain irradiation - a multicentre phase II study. Eur J Cancer 2002;38:1724-9.
66. Stewart DJ, Richard MT, Hugenholtz H, et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol 1984;2:133-9.
67. Stewart DJ, Leavens M, Friedman J, et al. Human central nervous system distribution of cis-diaminedichloroplatinum and its use as a radiosensitizer in malignant brain tumors. Cancer Res 1982;42:2474-9.
68. Stewart DJ, Lu K, Benjamin RS, et al. Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neurooncol 1983;1:139-44.
69. Green RM, Stewart DJ, Hogenholtz H, et al. Human central nervous system and plasma pharmacology of mitoxantrone. JNeurooncol 1988;6:75.
70. Orlando L, Curigliano G, Colleoni M, et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 2002;22:3057-9.
71. Cloughesy TF, Gobin YP, Black KL, et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 1997;35:121-31.
72. Newton HB, Slivka MA, Volpi C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 2003;61:35-44.
73. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78:255-60.
74. Bates S, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002;243:83-96.
75. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K. BIRICODAR (VX-710;Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer 1999;80:1190-6.
76. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005;312:44-52.
77. Abbott NJ, Revest PA. Control of brain endothelial permeability. Cerebrovasc Brain Metab Rev 1991;3:39-72.
78. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995;705:125-35.
79. Emerich DF, Snodgrass P, Dean R, et al. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 1999;80:964-70.
80. Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006;58:343-7.
81. Prados MD, Schold SC, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol 2003;5:96-103.
82. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999;16:1564-9.
83. Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001;92:1936-42.
84. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100:1199-207.
85. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996;93:14164-9.
86. Mazel M, Clair P, Rousselle C, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 2001;12:107-16.